Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants 10 December 2025
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants 08 December 2025
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss 08 December 2025
